Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1%–49%): TOPGAN2023-01

Abstract

IntroductionImmune checkpoint inhibitors (ICIs) plus chemotherapy is now a standard treatment for non-small cell lung cancer (NSCLC). Whether ICI plus chemotherapy (ICI-chemo) or ipilimumab plus nivolumab (I-N)-based therapy is superior for patients with NSCLC with a programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) of 1%–49% has not been evaluated. MethodsThis multicenter retrospective study included NSCLC patients with a TPS score of 1%–49%, who began first-line chemotherapy. Propensity score matching analysis was used to adjust for various confounders and evaluate treatment efficacy. ResultsA total of 401 patients were enrolled, of whom 308 received ICI-chemo and 93 received I-N-based therapy. The median OS was 21.0 months in the ICI-chemo group and 20.0 months in the I-N-based therapy group. After propensity score matching, there was no difference in OS or PFS between the ICI-chemo group and the I-N-based therapy group (OS: hazard ratios (HR), 0.83; 95% confidence interval [CI], 0.54–1.26, PFS: HR, 0.72; 95% CI, 0.52–1.00). Among PD-L1 TPS 25%–49%, there was a tendency for OS to be favorable for the ICI-chemo group (OS: HR, 0.30; 95% CI, 0.09–0.85). Treatment discontinuation occurred for 26.2% of the patients in the ICI-chemo group and 41.9% in the I-N-based therapy group. ConclusionsAmong PD-L1 TPS 1%–49%, there was no significant difference in survival outcomes between the ICI-chemo group and the I-N-based therapy group. Based on the results of a subgroup analysis, ICI-chemo may be superior for treating NSCLC with a TPS of 25%–49%.